Stay updated on KTE-C19 + Atezolizumab in DLBCL Clinical Trial
Sign up to get notified when there's something new on the KTE-C19 + Atezolizumab in DLBCL Clinical Trial page.

Latest updates to the KTE-C19 + Atezolizumab in DLBCL Clinical Trial page
- Check2 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0 from the page; no other content changes were observed.SummaryDifference0.0%

- Check9 days agoChange DetectedUI text updates include showing the glossary, capitalization changes in QC-related labels, and FEAR Act data and revision notes. These changes do not affect the study details, eligibility criteria, or results, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 on the page.SummaryDifference0.0%

- Check45 days agoChange DetectedA consolidated Locations section now lists California, Florida, Massachusetts, and Texas as study sites, replacing the separate location headers, and the page revision has been updated to v3.3.3.SummaryDifference0.4%

- Check74 days agoChange DetectedPublications section text updated to note PubMed auto-population of articles, and the page now displays Revision: v3.3.2. This replaces the earlier wording about PubMed publications and Revision: v3.2.0.SummaryDifference0.1%

- Check81 days agoChange DetectedA government funding status notice was removed from the page.SummaryDifference0.3%

Stay in the know with updates to KTE-C19 + Atezolizumab in DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KTE-C19 + Atezolizumab in DLBCL Clinical Trial page.